American Well (NYSE:AMWL) Insider Dmitry Zamansky Sells 6,243 Shares

American Well Corporation (NYSE:AMWL) insider Dmitry Zamansky sold 6,243 shares of American Well stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $4.85, for a total value of $30,278.55. Following the completion of the sale, the insider directly owned 191,468 shares in the company, valued at approximately $928,619.80. This represents a 3.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

American Well Price Performance

NYSE:AMWL traded up $0.36 during trading hours on Monday, reaching $5.21. 218,794 shares of the stock were exchanged, compared to its average volume of 179,997. The stock has a market cap of $85.35 million, a PE ratio of -0.72 and a beta of 1.26. American Well Corporation has a twelve month low of $3.71 and a twelve month high of $12.95. The firm has a 50 day moving average of $4.43 and a 200 day moving average of $6.15.

American Well (NYSE:AMWL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($1.74) EPS for the quarter, topping analysts’ consensus estimates of ($1.83) by $0.09. The business had revenue of $56.29 million for the quarter, compared to analyst estimates of $54.56 million. American Well had a negative net margin of 42.80% and a negative return on equity of 39.80%. Equities research analysts anticipate that American Well Corporation will post -9.34 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on AMWL. Weiss Ratings restated a “sell (e+)” rating on shares of American Well in a report on Wednesday, October 8th. Morgan Stanley cut their price objective on American Well from $10.50 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. Wells Fargo & Company reduced their target price on American Well from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Wall Street Zen cut American Well from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Stifel Nicolaus reduced their price objective on shares of American Well from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Wednesday, November 5th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.58.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AMWL. JPMorgan Chase & Co. raised its holdings in American Well by 16.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company’s stock valued at $131,000 after acquiring an additional 2,081 shares in the last quarter. Headlands Technologies LLC bought a new stake in American Well during the second quarter worth about $39,000. Senvest Management LLC grew its stake in American Well by 0.3% during the second quarter. Senvest Management LLC now owns 1,312,852 shares of the company’s stock worth $11,671,000 after buying an additional 4,497 shares in the last quarter. Two Sigma Investments LP increased its holdings in American Well by 22.6% in the 3rd quarter. Two Sigma Investments LP now owns 46,329 shares of the company’s stock valued at $285,000 after buying an additional 8,553 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of American Well during the 3rd quarter worth approximately $62,000. Institutional investors and hedge funds own 56.05% of the company’s stock.

American Well Company Profile

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.